232 related articles for article (PubMed ID: 22143063)
41. Hematopoietic cell transplantation for chronic lymphocytic leukemia: an evolving concept.
Kharfan-Dabaja MA; Anasetti C; Santos ES
Biol Blood Marrow Transplant; 2007 Apr; 13(4):373-85. PubMed ID: 17382245
[TBL] [Abstract][Full Text] [Related]
42. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
43. Allogeneic hematopoietic stem cell transplantation in Philadelphia-negative adult ALL: myeloablative, non-myeloablative, and beyond.
Hwang YY; Mohty M; Chim CS
Hematology; 2015 Mar; 20(2):61-71. PubMed ID: 24993587
[TBL] [Abstract][Full Text] [Related]
44. Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT).
Le Bourgeois A; Lestang E; Guillaume T; Delaunay J; Ayari S; Blin N; Clavert A; Tessoulin B; Dubruille V; Mahe B; Roland V; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Chevallier P
Eur J Haematol; 2013 Mar; 90(3):177-86. PubMed ID: 23301689
[TBL] [Abstract][Full Text] [Related]
45. Factors prognostic of eligibility for allogeneic HCT among older patients with AML-CR1 and adverse- or intermediate-risk cytogenetics.
Yamasaki S; Yoshimoto G; Ogawa R; Aoki K; Higuchi M; Harada N; Arima F; Kondo S; Matubara F; Takahashi T; Uike N; Miyamoto T; Okamura S; Akashi K;
Ann Hematol; 2015 Jul; 94(7):1159-65. PubMed ID: 25704584
[TBL] [Abstract][Full Text] [Related]
46. Viewpoint: What is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning--is there still an upper age limit? A focus on myeloid neoplasia.
Finke J; Nagler A
Leukemia; 2007 Jul; 21(7):1357-62. PubMed ID: 17508002
[TBL] [Abstract][Full Text] [Related]
47. Impact of Lung Function on Bronchiolitis Obliterans Syndrome and Outcome after Allogeneic Hematopoietic Cell Transplantation with Reduced-Intensity Conditioning.
Duque-Afonso J; Ihorst G; Waterhouse M; Zeiser R; Wäsch R; Bertz H; Müller-Quernheim J; Finke J; Marks R; Prasse A
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2277-2284. PubMed ID: 29964193
[TBL] [Abstract][Full Text] [Related]
48. Strategies to improve the outcome of stem cell transplantation in multiple myeloma.
Catley L; Anderson K
Hematol J; 2004; 5(1):9-23. PubMed ID: 14745425
[TBL] [Abstract][Full Text] [Related]
49. Identification of risk factors for bronchiolitis obliterans syndrome after reduced toxicity conditioning before hematopoietic cell transplantation.
Duque-Afonso J; Ihorst G; Wäsch R; Bertz H; Müller-Quernheim J; Finke J; Prasse A; Marks R
Bone Marrow Transplant; 2013 Aug; 48(8):1098-103. PubMed ID: 23376822
[TBL] [Abstract][Full Text] [Related]
50. Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
Chavez JC; Kharfan-Dabaja MA; Kim J; Yue B; Dalia S; Pinilla-Ibarz J; Anasetti C; Locke FL
Leuk Res; 2014 Oct; 38(10):1165-72. PubMed ID: 24889511
[TBL] [Abstract][Full Text] [Related]
51. What the internist should know about stem cell transplant in the elderly patient.
Medinger M; Passweg J
Eur J Intern Med; 2018 Dec; 58():43-47. PubMed ID: 29960832
[TBL] [Abstract][Full Text] [Related]
52. Novel therapies and their integration into allogeneic stem cell transplant for chronic lymphocytic leukemia.
Jaglowski SM; Byrd JC
Biol Blood Marrow Transplant; 2012 Jan; 18(1 Suppl):S132-8. PubMed ID: 22226097
[TBL] [Abstract][Full Text] [Related]
53. The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party.
Rubio MT; Savani BN; Labopin M; Polge E; Niederwieser D; Ganser A; Schwerdtfeger R; Ehninger G; Finke J; Renate A; Craddock C; Kröger N; Hallek M; Jindra P; Mohty M; Nagler A
J Hematol Oncol; 2016 Aug; 9(1):65. PubMed ID: 27488518
[TBL] [Abstract][Full Text] [Related]
54. Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: considerations for evidence-based GVHD prophylaxis.
Nakamura R; Forman SJ
Expert Rev Hematol; 2014 Jun; 7(3):407-21. PubMed ID: 24702163
[TBL] [Abstract][Full Text] [Related]
55. Reduced intensity conditioning allogeneic transplant for advanced chronic lymphocytic leukemia.
Soligo D; Motta M; Borsotti C; Ibatici A; Cortelezzi A; Lambertenghi Deliliers G
Haematologica; 2004 Jul; 89(7):885-6. PubMed ID: 15257953
[TBL] [Abstract][Full Text] [Related]
56. Impact of hyperferritinemia on the outcome of reduced-intensity conditioning allogeneic hematopoietic cell transplantation for lymphoid malignancies.
Barba P; Valcárcel D; Pérez-Simón JA; Fernández-Avilés F; Piñana JL; Martino R; López-Anglada L; Rovira M; Garcia-Cadenas I; Novelli S; Carreras E; López Corral L; Sierra J
Biol Blood Marrow Transplant; 2013 Apr; 19(4):597-601. PubMed ID: 23305680
[TBL] [Abstract][Full Text] [Related]
57. Outcomes of allogeneic haemopoietic stem cell transplants at a small New Zealand centre: does size matter?
Ganly P; Cole S; Trengrove A; Butler A
Intern Med J; 2014 Jul; 44(7):683-9. PubMed ID: 24750295
[TBL] [Abstract][Full Text] [Related]
58. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
Devillier R; Harbi S; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Etienne A; Calmels B; Lemarie C; Prebet T; Granata A; Charbonnier A; Rey J; Chabannon C; Faucher C; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1560-5. PubMed ID: 24933658
[TBL] [Abstract][Full Text] [Related]
59. Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, and the Societé Française de Greffe de Moelle et Therapie Cellulaire.
Xavier E; Cornillon J; Ruggeri A; Chevallier P; Cornelissen JJ; Andersen NS; Maillard N; Nguyen S; Blaise D; Deconinck E; Veelken H; Milpied N; Van Gelder M; Peffault de Latour R; Gluckman E; Kröger N; Schetelig J; Rocha V
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1515-23. PubMed ID: 25958294
[TBL] [Abstract][Full Text] [Related]
60. Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome.
Brown JR; Kim HT; Armand P; Cutler C; Fisher DC; Ho V; Koreth J; Ritz J; Wu C; Antin JH; Soiffer RJ; Gribben JG; Alyea EP
Leukemia; 2013 Feb; 27(2):362-9. PubMed ID: 22955330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
